Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Emotional distress19.04.02.008--Not Available
Blood phosphorus decreased13.11.01.015--Not Available
Blood phosphorus increased13.11.01.016--Not Available
Cerumen impaction04.01.01.001--Not Available
Band neutrophil count increased13.01.06.031--Not Available
Deep vein thrombosis24.01.02.0030.001875%Not Available
Self-injurious ideation19.12.01.007--Not Available
Madarosis23.02.02.004; 06.06.04.010--Not Available
Platelet count increased13.01.04.002--Not Available
Eyelids pruritus23.03.12.005; 06.08.03.007--Not Available
Sticky skin23.03.03.0190.001250%Not Available
Eye pruritus06.04.05.006--Not Available
Adenocarcinoma pancreas16.13.10.002; 07.21.09.003--Not Available
Drug tolerance decreased08.06.01.024--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.0020.001875%Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Lung neoplasm malignant16.19.02.001; 22.08.01.001--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Congenital eye disorder06.08.03.011; 03.01.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Embolism24.01.01.009--
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Lacrimal disorder06.08.02.005--Not Available
The 12th Page    First    Pre   12 13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene